An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Adicet Bio, Inc. (Nasdaq: ACET) granted an inducement award on April 30, 2024, to a new employee. The award consists of non-qualified stock options to purchase 7,800 shares at $1.49 per share. Vesting occurs over four years, with one-fourth vesting after one year and the rest in monthly installments. The award was granted outside Adicet's equity plans under the Inducement Plan.
Adicet Bio, Inc. (Nasdaq: ACET) ha concesso un premio di induzione il 30 aprile 2024 a un nuovo dipendente. Il premio consiste in opzioni su azioni non qualificate per l'acquisto di 7.800 azioni al prezzo di $1.49 ciascuna. L'assegnazione delle opzioni avverrà su un periodo di quattro anni, con un quarto delle opzioni che verrà assegnato dopo un anno e il resto in rate mensili. Il premio è stato concesso al di fuori dei piani di equity di Adicet secondo il Piano di Induzione.
Adicet Bio, Inc. (Nasdaq: ACET) otorgó un premio de inducción el 30 de abril de 2024 a un nuevo empleado. El premio consiste en opciones de acciones no calificadas para comprar 7,800 acciones a $1.49 por acción. La adquisición de estas opciones se produce a lo largo de cuatro años, con un cuarto de ellas que se otorga después de un año y el resto en cuotas mensuales. El premio fue concedido fuera de los planes de capital de Adicet bajo el Plan de Inducción.
Adicet Bio, Inc.(나스닥: ACET)는 2024년 4월 30일 새로운 직원에게 유인상을 부여하였습니다. 상은 비자격 주식 옵션으로, 주당 $1.49에 7,800주를 구매할 수 있습니다. 주식 옵션의 귀속은 4년 동안 이루어지며, 첫 해 후 4분의 1이 귀속되고 나머지는 매월 분할됩니다. 이 상은 Adicet의 자본 계획 외부에서 유인 계획에 따라 부여되었습니다.
Adicet Bio, Inc. (Nasdaq : ACET) a accordé une récompense d'incitation le 30 avril 2024 à un nouvel employé. La récompense consiste en des options d'achat d'actions non qualifiées pour acquérir 7,800 actions à $1.49 l'unité. L'acquisition des options se déroule sur quatre ans, avec un quart acquit après un an et le reste en versements mensuels. La récompense a été accordée en dehors des plans d'actions de Adicet selon le Plan d'Incitation.
Adicet Bio, Inc. (Nasdaq: ACET) hat am 30. April 2024 einem neuen Mitarbeiter eine Anreizprämie gewährt. Diese Prämie besteht aus nicht-qualifizierten Aktienoptionen für den Kauf von 7.800 Aktien zu einem Preis von $1.49 pro Aktie. Die Vesting-Periode erstreckt sich über vier Jahre, wobei ein Viertel nach einem Jahr verfällt und der Rest in monatlichen Raten. Die Prämie wurde außerhalb der Adicet-Eigenkapitalpläne gemäß dem Anreizplan gewährt.
Positive
None.
Negative
None.
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on April 30, 2024.
One individual was hired by Adicet in April 2024 and granted new hire non-qualified stock options to purchase 7,800 shares of Adicet’s common stock with an exercise price of $1.49 per share, the closing price of Adicet’s common stock as reported by Nasdaq on April 30, 2024. One-fourth of the shares underlying the employee’s option will vest on the one-year anniversary of the recipient’s start date and thereafter the remaining three-fourths of the shares underlying the employee’s option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to the employee will be fully vested on the fourth anniversary of the recipient’s start date, subject to the employee’s continued employment with Adicet on such vesting dates.
The above-described award was granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The award was authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v
